Philips Creates Global Clinical Advisory Board of 12 Experts for Sonicare Brand
In a press release published in Amsterdam on October 8, 2026, Royal Philips announced the creation of the Philips Sonicare Global Clinical Advisory Board, a clinical advisory board composed of specialists external to the group. Designed as a long-term collaboration, the body is intended to integrate the perspective of dental professionals into the product roadmap of the Oral Healthcare division.
Three Missions: Strategic Guidance, R&D and Clinical Exploration
According to the group, the board will have three missions: provide strategic guidance on emerging trends, support science-based product development and contribute to new clinical explorations. Philips presents the initiative as an ongoing exchange with global experts, intended to advance evidence-based oral healthcare.
The group justifies this approach by the evolution of the sector: according to the press release, dental professionals and patients are seeking clearer recommendations, more personalized routines and solutions based on clinical and scientific data. The stated objective is to bring external expertise closer to the innovation process.
"The Global Clinical Advisory Board helps us continue to develop evidence-based innovations that meet the needs of professionals and the people they care for," said Francesco Grillo, Global Head of Philips' Oral Healthcare unit.
Profiles from Research, Clinical Practice and Teaching
The 12 members cover clinical practice, research, teaching, behavioral change, digital dentistry and oral health innovation. The majority are academics, including Purnima Kumar (University of Michigan), Iain Chapple (University of Birmingham) and Dagmar Else Slot (Academic Centre for Dentistry Amsterdam).
France is represented by Virginie Monnet-Corti, Professor and Head of the Department of Periodontics at Aix-Marseille University and Timone Hospital (AP-HM). The board also includes members practicing in Switzerland, China, Poland, Slovakia, Turkey, the United Kingdom and the United States, including two practitioners in private practice or clinic.
For Andrew Bower, Head of the Dental Professional & Strategic Adjacencies category, the board should help Philips Sonicare "anticipate the evolution of the profession" and translate expert opinion into innovations.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
SectorDispositifs médicaux et optique›Dispositifs médicaux
Context
Period
Period: T3 2026
Key reported figures
Revenue: 4 393 millions d'euros
Quarterly revenue: 4 393 millions d'euros
Revenue growth: 2 %
Net income: 27 millions d'euros
Free cash flow: 384 millions d'euros
5 387 millions d'euros
Guidance from the release
« Our year-to-date results, together with our strong order book, give us confidence in delivering our full-year outlook and achieving our medium-term ambitions. » ; « Philips reiterates its full-year 2026 outlook »
Risks mentioned
Macro-economic and geopolitical changes including war in Ukraine and Middle East tensions, plus enacted and proposed tariffs and trade actions
Respironics-related legal proceedings and ongoing investigation by US State Attorneys General excluded from 2026 outlook
Phasing of Ultrasound sales and lower sales in China as previously communicated at Q2
Opportunities identified
Strong demand for latest AI-enabled innovations including new CT platforms Verida and Rembra, ultrasound system Alturion, and HealthSuite Imaging cloud solution
Accelerating innovation in image-guided therapy with EUR 50 million investment in AI, robotics and advanced imaging in Netherlands, plus EUR 150 million in private financing
Extended monitoring partnership with largest US health system through 2034 and expansion of Capsule platform, plus strategic partnerships in China and Latin America
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.